7.93

1.28% 0.10

Aurinia Pharmaceuticals Inc (AUPH)

Overview News Price History Option Chain Financials Why AUPH Down? Discussions Forecast Stock Split

Aurinia Pharmaceuticals Inc stock is traded at $7.93, with a volume of 1.10M. It is up +1.28% in the last 24 hours and up +2.59% over the past month. Aurinia Pharmaceuticals Inc is a biopharmaceutical company. It provides products for patients suffering from serious diseases with a high unmet medical need. The firm is developing LUPKYNIS (voclosporin), an investigational drug, for the treatment of lupus nephritis (LN), and others. Geographically, it derives maximum revenue from the United States.

Previous Close:

$7.83

Open:

$7.92

24h Volume:

1.10M

Relative Volume:

0.85

Market Cap:

$1.14B

Revenue:

$175.51M

Net Income/Loss:

$-78.02M

P/E Ratio:

-14.96

EPS:

-0.53

Net Cash Flow:

$-34.18M

1W Performance:

+1.80%

1M Performance:

+2.59%

6M Performance:

+20.33%

1Y Performance:

+38.15%

1-Day Range:

$7.785

$7.96

1-Week Range:

$7.502

$8.095

52-Week Range:

$4.71

$10.67

Aurinia Pharmaceuticals Inc Stock (AUPH) Company Profile

Name

Aurinia Pharmaceuticals Inc

Sector

Healthcare (1169)

Industry

Biotechnology (678)

Phone

250-744-2487

Address

#140, 14315 - 118 AVENUE, EDMONTON, BC

Employee

300

Twitter

@AuriniaPharma

Next Earnings Date

2024-11-07

Latest SEC Filings

AUPH's Discussions on Twitter

Compare AUPH with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
AUPH Aurinia Pharmaceuticals Inc	7.93	1.14B	175.51M	-78.02M	-34.18M	-0.53
VRTX Vertex Pharmaceuticals Inc	484.24	124.35B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	700.33	76.56B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	644.48	39.16B	1.86B	-40.29M	-1.28B	-0.85
ALNY Alnylam Pharmaceuticals Inc	250.59	32.44B	2.25B	-278.16M	-42.59M	-2.17
BNTX Biontech Se Adr	120.01	28.77B	3.30B	-501.07M	1.03B	-2.1146

Aurinia Pharmaceuticals Inc Stock (AUPH) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Nov-04-22	Downgrade	Oppenheimer	Outperform → Perform
May-05-22	Resumed	Cantor Fitzgerald	Overweight
Dec-10-21	Upgrade	Oppenheimer	Perform → Outperform
Oct-28-21	Downgrade	Oppenheimer	Outperform → Perform
Jan-25-21	Reiterated	H.C. Wainwright	Buy
Nov-03-20	Reiterated	H.C. Wainwright	Buy
Jun-17-20	Initiated	BTIG Research	Buy
May-05-20	Initiated	Cowen	Outperform
Jan-10-20	Initiated	Jefferies	Buy
Dec-16-19	Reiterated	H.C. Wainwright	Buy
Mar-16-18	Reiterated	Cantor Fitzgerald	Overweight
Feb-08-18	Initiated	RBC Capital Mkts	Outperform
Oct-30-17	Reiterated	H.C. Wainwright	Buy
May-18-17	Reiterated	H.C. Wainwright	Buy
Apr-11-17	Initiated	Cantor Fitzgerald	Overweight
Mar-22-17	Reiterated	FBR & Co.	Outperform
Dec-30-16	Reiterated	H.C. Wainwright	Buy
Aug-17-16	Reiterated	H.C. Wainwright	Buy
Jun-30-16	Initiated	H.C. Wainwright	Buy
May-08-15	Initiated	MLV & Co	Buy

View All

Aurinia Pharmaceuticals Inc Stock (AUPH) Latest News

Feb 21, 2025

(AUPH) On The My Stocks Page - Stock Traders Daily

Feb 21, 2025

Aurinia Pharmaceuticals: There's Still Time For Sales Growth (NASDAQ:AUPH) - Seeking Alpha

Feb 21, 2025

Feb 20, 2025

Aurinia Pharmaceuticals (AUPH) to Release Earnings on Thursday - MarketBeat

Feb 20, 2025

When Will Aurinia Report Q4 Earnings? Key Date and Details for Investors - StockTitan

Feb 20, 2025

Feb 19, 2025

Aurinia Pharmaceuticals (NASDAQ:AUPH) Rating Lowered to Buy at StockNews.com - MarketBeat

Feb 19, 2025

retail investors who own 52% along with institutions invested in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) saw increase in their holdings value last week - Simply Wall St

Feb 19, 2025

Compagnie Lombard Odier SCmA Cuts Stock Holdings in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) - MarketBeat

Feb 19, 2025

Short Interest in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Grows By 25.5% - MarketBeat

Feb 19, 2025

Feb 18, 2025

Aurinia (AUPH) Upgraded to Buy: Here's Why - MSN

Feb 18, 2025

Head-To-Head Analysis: Aurinia Pharmaceuticals (NASDAQ:AUPH) vs. XBiotech (NASDAQ:XBIT) - Defense World

Feb 18, 2025

Feb 16, 2025

Aurinia Pharmaceuticals (AUPH) Projected to Post Quarterly Earnings on Thursday - MarketBeat

Feb 16, 2025

Feb 14, 2025

Aurinia Pharmaceuticals (NASDAQ:AUPH) Downgraded by StockNews.com to Buy - MarketBeat

Feb 14, 2025

Feb 13, 2025

Aurinia Pharmaceuticals (NASDAQ:AUPH) Share Price Crosses Below 50 Day Moving AverageWhat's Next? - MarketBeat

Feb 13, 2025

Aurinia Pharmaceuticals (AUPH) to Release Quarterly Earnings on Thursday - Defense World

Feb 13, 2025

Feb 11, 2025

Perhaps timely catching Aurinia Pharmaceuticals Inc (AUPH) would be a good idea - SETE News

Feb 11, 2025

Aurinia Pharmaceuticals (NASDAQ:AUPH) Lowered to Buy Rating by StockNews.com - Defense World

Feb 11, 2025

Objective long/short (AUPH) Report - Stock Traders Daily

Feb 11, 2025

Feb 10, 2025

A Guide To The Risks Of Investing In Aurinia Pharmaceuticals Inc (AUPH) - Knox Daily

Feb 10, 2025

Feb 07, 2025